Ligand Pharmaceuticals Reports Q3 Earnings Beat and Raises 2026 Adjusted EPS Guidance
Ligand Pharmaceuticals (LGND) reported third-quarter financial results that exceeded analyst expectations on both the top and bottom lines. The company posted a Non-GAAP earnings per share (EPS) of $2.67, beating consensus by $0.34, while revenue reached $78.75 million, surpassing estimates by $1.52 million despite a 31.8% year-over-year decline. Looking ahead, Ligand has raised its full-year 2026 adjusted earnings per diluted share guidance to a range of $9.50 to $9.75, significantly higher than the previous guidance and the consensus estimate of $5.27. While the company reaffirmed its total revenue guidance for 2026 at $270 million to $310 million, the upward revision in earnings reflects strong profitability outlooks.
Tickers: $LGND
Topics: earnings report EPS beat guidance raise revenue beat